Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Cho

Showing results (131-140 of 178) with videos related to

Pageof 18
Sort By:
Journal of the American College of Cardiology|July 3, 2024
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin DrugsA Michael Lincoff, Kausik K Ray, William J Sasiela, et al.
Journal of the American Heart Association|June 11, 2025
What Every Cardiologist Should Know About Contraception and Reproductive Planning in 2025Leslie Cho, Joan E Briller, Haywood L Brown, et al.
JACC. Advances|March 15, 2025
Sex Hormones and Heart Failure RiskImo A Ebong, Duke Appiah, Rina Mauricio, et al.
Circulation|February 13, 2023
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?Leslie Cho, Andrew M Kaunitz, Stephanie S Faubion, et al.
Journal of the American College of Cardiology|August 23, 2023
Sex Differences in Thoracic Aortic Disease and Dissection: JACC Review Topic of the WeekDaniela Crousillat, Joan Briller, Niti Aggarwal, et al.
Diabetes Care|December 7, 2019
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATENishant P Shah, Qiuqing Wang, Katherine E Wolski, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Journal of the American College of Cardiology|April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabErik Stroes, David Colquhoun, David Sullivan, et al.
Current Cardiology Reports|August 19, 2021
Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and GuidelinesAnas Alameh, Ahmad Jabri, Wesam Aleyadeh, et al.
American Heart Journal|April 29, 2006
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialMatthews Chacko, A Michael Lincoff, Katherine E Wolski, et al.
Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
Journal of the American College of Cardiology|July 3, 2024
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin DrugsA Michael Lincoff, Kausik K Ray, William J Sasiela, et al.
Journal of the American Heart Association|June 11, 2025
What Every Cardiologist Should Know About Contraception and Reproductive Planning in 2025Leslie Cho, Joan E Briller, Haywood L Brown, et al.
JACC. Advances|March 15, 2025
Sex Hormones and Heart Failure RiskImo A Ebong, Duke Appiah, Rina Mauricio, et al.
Circulation|February 13, 2023
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?Leslie Cho, Andrew M Kaunitz, Stephanie S Faubion, et al.
Journal of the American College of Cardiology|August 23, 2023
Sex Differences in Thoracic Aortic Disease and Dissection: JACC Review Topic of the WeekDaniela Crousillat, Joan Briller, Niti Aggarwal, et al.
Diabetes Care|December 7, 2019
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATENishant P Shah, Qiuqing Wang, Katherine E Wolski, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Journal of the American College of Cardiology|April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabErik Stroes, David Colquhoun, David Sullivan, et al.
Current Cardiology Reports|August 19, 2021
Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and GuidelinesAnas Alameh, Ahmad Jabri, Wesam Aleyadeh, et al.
American Heart Journal|April 29, 2006
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialMatthews Chacko, A Michael Lincoff, Katherine E Wolski, et al.
Pageof 18